|
|
News Breaks | | | | October 22, 2012 | | 10:01 EDT |  | CVM | CEL-SCI announces results of interim review of data from Phase III trial
CEL-SCI Corporation announced that an interim review of the safety data from its open label, randomized, controlled, pivotal Phase III study of Multikine investigational immunotherapy by an Independent Data Monitoring Committee raised no safety concerns. The IDMC also indicated that no safety signals were found that would call into question the benefit/risk of continuing the study. CEL-SCI considers the results of the IDMC review to be important since studies have shown that up to 30% of Phase III trials fail due to safety considerations and the IDMC’s safety findings from this interim review were similar to those reported by investigators during CEL-SCI’s Phase I-II trials. Ultimately, the decision as to whether a drug is safe is made by the FDA based on an assessment of all of the data from a trial. | |
|
News For CVM From The Last 14 Days Check below for free stories on CVM the last two weeks. |
|
|
| There are no results for CVM |
|
|
|
|
|
|
